Co-Authors
This is a "connection" page, showing publications co-authored by HARMEET KAUR and JEAN NICOLAS VAUTHEY.
Connection Strength
0.350
-
RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015 Mar; 22(3):834-842.
Score: 0.127
-
Evaluating the Clinical Applicability of the European Staging System for Perihilar Cholangiocarcinoma. J Gastrointest Surg. 2016 Apr; 20(4):741-7.
Score: 0.035
-
Intrabiliary growth of colorectal liver metastasis: spectrum of imaging findings and implications for surgical management. AJR Am J Roentgenol. 2013 Oct; 201(4):W582-9.
Score: 0.030
-
Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy. Pract Radiat Oncol. 2014 May-Jun; 4(3):167-173.
Score: 0.029
-
Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47.
Score: 0.029
-
SSAT/AHPBA joint symposium on evaluation and treatment of benign liver lesions. J Gastrointest Surg. 2013 Apr; 17(4):636-44.
Score: 0.028
-
CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. AJR Am J Roentgenol. 2011 Dec; 197(6):W1060-6.
Score: 0.026
-
Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010 Sep; 34(9):1287-94.
Score: 0.024
-
Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009 Dec 02; 302(21):2338-44.
Score: 0.023